• Dental Practice Management
Formulary Watch
Formulary Watch
Spotlight
Clinical
News
Media
FDA
Partner Content
Subscribe
  • Advertise
  • Editorial Info
  • Contact Us
  • Terms & Conditions
  • Privacy Policy
  • Do Not Sell My Personal Information

© 2021 MJH Life Sciences and Formulary Watch. All rights reserved.

Spotlight
  • COPD
ClinicalSee All >
  • Allergy, Immunology, and ENT
  • Cardiovascular
  • Clinical Pharmacology
  • COPD
  • Dermatology
  • Diabetes and Endocrinology
  • Idiopathic Pulmonary Fibrosis
  • Musculoskeletal / Rheumatology
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Pediatrics
  • Pharmacy
  • Psychiatry and Behavioral Health
  • Respiratory
  • Urology
  • Advertise
  • Editorial Info
  • Contact Us
  • Terms & Conditions
  • Privacy Policy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Formulary Watch. All rights reserved.

US alleges Novartis paid kickbacks to specialty pharmacies

July 2, 2015

In a new lawsuit, the U.S. government alleges Novartis paid kickbacks to specialty pharmacies to increase sales of deferasirox (Exjade), which removes excess iron from the blood of patients who receive transfusions, and mycophenolic acid (Myfortic), to prevent rejection of kidney transplants.

In a new lawsuit, the US government alleges Novartis paid kickbacks to specialty pharmacies to increase sales of deferasirox (Exjade), which removes excess iron from the blood of patients who receive transfusions, and mycophenolic acid (Myfortic), to prevent rejection of kidney transplants.

Related: 7 strategies for managing the rise in specialty drugs costs

In the suit, filed in US District Court in Manhattan, the United States is seeking as much as $3.3 billion in damages. A group of specialty pharmacies submitted thousands of fraudulent reimbursement claims to Medicare and Medicaid for the 2 drugs, according to the lawsuit, Bloombergreported. Novartis paid kickbacks in the form of rebates, so the pharmacies would recommend the drugs to patients and boost sales, according to the suit.

Related:Specialty drug coverage varies across health plans

Novartis said it provided legitimate rebates to the pharmacies in the court filing. The company “continues to dispute the allegations and is continuing to defend itself in this litigation,” Novartis said in a statement to Bloomberg. “We look forward to a full presentation of all of the evidence during the trial.”

Read next: High healthcare costs driven by spike in Rx costs

Related Content:

News